Company intelligence / Profile preview
Zhejiang Shapuaisi Pharmaceutical
- Ownership
- Private
- Employees
- ~1328
- Development stage
- Other
Overview
Zhejiang Shapuaisi Pharmaceutical has commercialized ophthalmic and antimicrobial drugs in China. It has ongoing clinical programs including a Phase 3 trial of azithromycin eye drops for purulent bacterial conjunctivitis and a Phase 2 program with bendazac lysine targeting diabetic nephropathies. The company also markets benzalkonium chloride eye drops and cefixime products. Its business includes both pharmaceutical sales and specialty medical services focused on ophthalmology.
- Therapeutic areas
- NephrologyOphthalmologyInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
Drug pipeline
1 assetBeyond the preview
Go deeper on Zhejiang Shapuaisi Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhejiang Shapuaisi Pharmaceutical.